JJP Biologics announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants with their potential first-in-class anti-CD89 antagonist, JJP-1212.
JJP Biologics announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants with their potential first-in-class anti-CD89 antagonist, JJP-1212.